Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CYP2D6 genotype and associated 5-HT3 receptor antagonist outcomes: A systematic review and meta-analysis.

Clinical and translational science - 1 Feb 2025

Moore Claire, Williams Elizabeth, Dyas Roxanne, Halman Andreas, Stenta Tayla, Khatri Dhrita, Elliott David A, Lange Peter W, Caudle Kelly E, Conyers Rachel

Abstract excerpt

5-hydroxytryptamine-3 (5-HT3) receptor antagonists including ondansetron, tropisetron, dolasetron, palonosetron, granisetron, and ramosetron are commonly used to prevent and treat nausea and vomiting. Most of these medications are at least partially metabolized via the highly polymorphic CYP2D6 enzyme, resulting in variations of metabolism among individuals. Current (2017) international prescribing guidelines for...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cytochrome P-450 CYP2D6
Share to Genotype

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Pharmacogenetics

Share to Pharmacogenomic Variants

Share to Treatment Outcome

Source

Open in PubMed Open full text

Identifiers

PMID: 39899439
DOI: 10.1111/cts.70108
PMCID: PMC11789932

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CYP2D6 genotype and associated 5-HT3 receptor antagonist outcomes: A systematic review and meta-analysis.PMID 39899439Read ↗

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 Genotype and Use of 5-HT3 Receptor Antagonists: 2026 Update.Semantic proximity Read ↗

Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline forCYP2D6genotype and use of ondansetron and tropisetronSemantic proximity Read ↗

The efficacy of 5HT3-receptor antagonists in postoperative nausea and vomiting: the role of pharmacogeneticsSemantic proximity Read ↗

Cytochrome P450 2D6 metabolism and 5-hydroxytryptamine type 3 receptor antagonists for postoperative nausea and vomiting.Semantic proximity Read ↗

Interethnic differences in genetic polymorphisms of CYP2D6 in the U.S. population: clinical implications.Semantic proximity Read ↗

CYP2D6- and CYP3A-dependent enantioselective plasma concentrations of ondansetron in postanesthesia care.Semantic proximity Read ↗

Prevention of postoperative nausea and vomiting with granisetron and dolasetron in relation to CYP2D6 genotype.Semantic proximity Read ↗

Does pharmacogenomics account for variability in control of acute chemotherapy-induced nausea and vomiting with 5-hydroxytryptamine type 3 receptor antagonists?Semantic proximity Read ↗

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants.Semantic proximity Read ↗

CYP2D6 basic genotyping as a potential tool to improve the antiemetic efficacy of ondansetron in prophylaxis of postoperative nausea and vomiting.Semantic proximity Read ↗

Association between CYP2D6 genotype and treatment effectiveness and safety in 99 hospitalized patients with major depressive disorder - a retrospective cohort studySemantic proximity Read ↗

Patient-tailored antiemetic treatment with 5-hydroxytryptamine type 3 receptor antagonists according to cytochrome P-450 2D6 genotypes.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.